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ABSTRACT
Cancers are heterogeneous and genetically
unstable. New methods are needed that provide
the sensitivity and specificity to query single cells
at the genetic loci that drive cancer progression,
thereby enabling researchers to study the progres-
sion of individual tumors. Here, we report the
development and application of a bead-based
hemi-nested microfluidic droplet digital PCR
(dPCR) technology to achieve ‘quantitative’ meas-
urement and single-molecule sequencing of somat-
ically acquired carcinogenic translocations at
extremely low levels (<106) in healthy subjects.
We use this technique in our healthy study popula-
tion to determine the overall concentration of the
t(14;18) translocation, which is strongly associated
with follicular lymphoma. The nested dPCR
approach improves the detection limit to 1 107
or lower while maintaining the analysis efficiency
and specificity. Further, the bead-based dPCR
enabled us to isolate and quantify the relative
amounts of the various clonal forms of t(14;18)
translocation in these subjects, and the single-
molecule sensitivity and resolution of dPCR led to
the discovery of new clonal forms of t(14;18) that
were otherwise masked by the conventional quanti-
tative PCR measurements. In this manner, we
created a quantitative map for this carcinogenic
mutation in this healthy population and identified
the positions on chromosomes 14 and 18 where
the vast majority of these t(14;18) events occur.
INTRODUCTION
Tumor-specific somatic mutations can provide highly
useful molecular biomarkers and therapeutic targets for
cancer diagnosis, prognosis and treatment. Central to
the use of these genetic biomarkers in clinical oncology
is sensitive and quantitative measurement of rare muta-
tions in a vast excess of wild-type alleles. For instance,
discovering driver mutations that lead to carcinogenesis
in a rare subset of cells is one key approach to the risk
assessment, early detection and treatment of cancer (1,2).
Investigation of genetic variants in rare circulating tumor
cells in metastatic cancer patients would help understand
the biology of metastasis and development of drug resist-
ance in chemotherapy (3). Moreover, quantification of
low-level mutated sequences in cancer patients during
and after treatments can provide informative data for
evaluating therapy efficacy, monitoring minimal residual
diseases and detecting disease relapse (4).
In recent years, technical advances have enormously
improved the capacity to analyze genetic variants,
yielding novel methods for the detection of rare mutations
(5). For instance, quantitative PCR (qPCR), a widely used
approach in genetic analysis, measures the analog fluores-
cence signal of targets and thus is limited in the detection
sensitivity and/or quantification accuracy owing to instru-
mental and experimental variation. An attractive alterna-
tive to this analog technique is digital PCR (dPCR), which
provides a superior sensitivity to conventional qPCR by
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allowing absolute quantification of target molecules (6–9).
Here, we report the development and application of a
bead-based hemi-nested microfluidic digital droplet PCR
(simplified as nested dPCR hereafter) approach to achieve
‘quantitative’ measurement of somatically acquired car-
cinogenic translocations at extremely low levels (<106)
in healthy subjects. This sensitive nested dPCR approach
has an overall clinical sensitivity that is mainly limited by
the amount of DNA that is available for screening (10). In
contrast to other dPCR methods using emulsion droplets
(8,9), our bead-based dPCR approach provides not only
superior quantification performance at extremely low
levels but also the capacity to sequence and quantify
each mutated clone in a subject after millions of discrete
single molecule reactions are conducted in parallel.
Therefore, this novel dPCR method can be used to
measure the amounts of various clones within a subject
or population over time and thus monitor for clonal
expansion before clinical disease progression.
The model translocation that we chose for technology
validation, the BCL-2/immunoglobulin heavy chain (IgH)
translocation t(14;18), is highly prevalent in many blood
cancers, including 80% of follicular lymphoma (FL)
cases and 25% of large-cell B-cell lymphoma cases
(11,12). The translocation brings the B-cell lymphoma-2
(BCL2) gene from 18q21 under the control of the strong
enhancers of the IgH locus, ultimately disrupting BCL2’s
normal pattern of expression in B cells (13,14). BCL2 is an
anti-apoptotic protein, and its overexpression can be in-
timately involved in the pathogenesis of B-cell neoplasms
(15). t(14;18) is found in a relatively small fraction of the
peripheral blood mononuclear cells (PBMCs) of healthy
individuals and may be a biomarker of early lymphoma
(16–18). The mutation concentration in healthy individ-
uals is 1000-fold lower than for individuals with stage
III/IV FL(10), and it is believed that clonal expansion of
atypical B cells is required for lymphoma progression
(16,18–20). t(14;18) prevalence at any level in healthy
populations has been reported in the range of 8–88%,
which reflects the differences both in the populations
studied and in the techniques used to assay t(14;18)
(17,21,22). Thus ‘highly sensitive and quantitative detec-
tion’ of t(14;18) is essential for fully investigating the
clinical value of t(14;18) for risk assessment and early
diagnosis of lymphoma. Furthermore, clinical studies
have observed clonal evolution of t(14;18) associated
with disease progression in individual patients (23). A
high-throughput technique that can sequence and
quantify multiple t(14;18)+ clones could provide insight
into the molecular pathology and clinical importance of
t(14;18) (24,25).
Using the nested microfluidic dPCR method, we were
able to quantitatively detect and sequence a single t(14;18)
copy in 9 mg (3 106 copies) of clot genomic DNA
(gDNA) from individuals in a healthy study population.
We also applied nested dPCR to develop a quantitative
genomic map of t(14;18) by sequencing and quantifying
the unique t(14;18) clones found in individual subjects
within this study population. The genomic map that we
produced represents a baseline for this healthy population,
and further sampling of this population can be used to
monitor for expansion of particular clonal forms as part
of disease progression.
MATERIALS AND METHODS
Study subjects
The formaldehyde-exposed worker population, exposure
assessment and biological sampling from the study
subjects were described in detail in the Supplementary
Methods.
Cell culture
Cell lines of t(14;18) TK6 (CRL 8015) and t(14;18)+RL
(CRL 2261) (ATCC, Manassas, VA) lymphoblasts were
maintained in RPMI 1640 medium (Gibco, Carlsbad, CA)
supplemented with 10% fetal bovine serum (FBS) (Omega
Scientific, Tarzana, CA) at a cell density of
(2 105 2 106)/ml and incubated at 37C in a 5%
CO2 atmosphere.
Cell and gDNA purification
We used Clotspin baskets and the Gentra Puregene
blood kit (Qiagen, CA) to purify clot gDNA. Buffy coat
was prepared by spinning whole blood at 200g for 10min
and then by removing the concentrated leukocyte band.
We then isolated DNA using the FlexiGene DNA kit
(Qiagen). PBMCs were purified from whole blood using
density gradient centrifugation through Ficoll-PaqueTM
PLUS following the manufacturer’s recommendations
(GE Healthcare, NJ). To purify gDNA from cell lines
and PBMCs, we used a standard cell lysis with RNA
and protein digests followed by a phenol–chloroform
DNA extraction. The quality of gDNA was assessed,
and copy number was normalized using qPCR for
b-actin. For more detail regarding gDNA extraction and
quality assessment, please see the Supplementary
Methods.
Microfluidic droplet-based dPCR
The four-channel Microfabricated emulsion generator
array (MEGA) devices were constructed and operated as
detailed previously (26). For droplet generation, freshly
prepared carrier oil was injected into the oil channels by
a syringe pump, and droplet dPCR mix containing
t(14;18) amplicon and primer-conjugated beads was
driven by the on-chip diaphragm pump, which was pneu-
matically actuated by a solenoid valve controller system
built in house. The pumping was conducted in a four-step
fashion under the control of a LABVIEW program to
produce uniform 2.5 nl of PCR droplets, which were
collected in 0.5ml of PCR tubes filled with microfine
emulsion. Thermal cycling was carried out in a PTC200
thermocycler (MJ Research) and involved a 10min hot
start at 95C, and 33 cycles of 95C for 30 s, 60C for
60 s, 72C for 90 s and a final 72C extension for 5min.
The beads were then recovered by using a 15 mm of mesh
filter, rinsed with isopropanol, ethanol and 1 Dulbecco’s
PBS (DPBS, GIBCO) and analyzed by a multicolor flow
cytometer (FC-500, Beckman-Coulter). More details
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regarding chip fabrication, droplet generation, PCR con-
dition and bead handling and flow cytometry were
provided in the Supplementary Methods.
Hemi-nested PCR
All oligonucleotides (Supplementary Table S3) used in
this study were obtained from IDT (Coralville, IA), and,
unless otherwise noted, PCR reagents were from Life
Technologies (Carlsbad, CA). The pre-amplification
(preamp) reaction mix contained 1 Ampli Taq Gold
buffer with 5mM MgCl2, 0.2mM deoxyribonucleotide
triphosphates (dNTPs) (deoxyuridine triphosphate
(dUTP) was used at 0.4mM instead of deoxythymidine
triphosphate (dTTP)), 0.01U ml1 of uracil-DNA
glycosylase (UDG) (Roche), 2.5% dimethyl sulfoxide
(DMSO), 0.3 mM each of the oligonucleotides (JH Exo
and RT0001), 0.035U ml1 of Ampli Taq Gold
Polymerase and 3 mg of gDNA per 50 ml reaction.
Thermal cycling in an ABI GeneAmp 9700 cycler
consisted of a UDG reaction (50C for 2min), followed
by a 10min hot start at 95C and 20 cycles of 95C for
15 s, 60C for 30 s, and 72C for 30 s. The hemi-nested
reaction mix contained the same components as the
preamp mix except that 1 mM ROX reference dye, 0.3mM
each of the primers (JH Exo, Nv3, and BCL2MBRTM2)
and 1 ml of the preamp reaction product were used instead.
Thermal cycling in anABI 7300 cycler consisted of a 10min
hot start at 95C, and 33 cycles of 95C for 15 s, 60C for
30 s and 72C for 30 s. Standards made by diluting RL
gDNA in TK6 gDNA were used to establish a calibration
curve for t(14;18) quantification (Figure 1 and
Supplementary Figure S2). Each assay plate included
three standards (102, 101 and 3 copies in 3 mg) and a
negative control (3 mg of TK6 DNA) to ensure robust
and specific detection at the level of 1 copy/mg. Positive
reactions were run on a 1.5% agarose gel to separate
amplicons that were then excised, purified using a
QIAquick Gel Extraction Kit (QIAGEN) and sequenced
at the UC Berkeley Core Sequencing Facility.
Single-molecule sequencing
Amplicon-bound beads from dPCR were counted using a
hemocytometer, plated in 96-well PCR plates at 1 bead
per well, and re-amplified using the hemi-nested PCR con-
ditions described in the last section. DNA amplicons
yielded from single beads were sequenced following the
method described earlier in the text. Sequencing reads
were aligned to the reference assembly of the human
genome using NCBI’s nucleotide basic local alignment
search tool (BLASTn). The ‘N sequence’ insert was
identified as the de novo sequence found between the two
breakpoints in a particular translocation clone. To map
the locations of the V(D)J recombination signal sequences
(RSSs), we mapped all allowable RSS nonamers and
heptamers to the chromosome 14 contig (NT_026437.11)
and then found nonamer–heptamer pairs that were
separated by appropriately sized spacer sequences
(Figure 5 and Supplementary Figure S6). More details
about single-molecule sequencing and sequence analysis
were discussed in the Supplementary Methods.
RESULTS
Digital quantitation and single-molecule sequencing of
t(14;18): method design and performance
We found that our standard qPCR method was not
sensitive enough to quantify and sequence t(14;18) from
the clot gDNA of healthy subjects (Supplementary
Figure S1); therefore, we developed a nested PCR
approach (Figure 1a and c) for digital analysis of
t(14;18). This approach starts with a preamp reaction
(Figure 1b), and the resultant target copies are then
quantified and sequenced using both a conventional
nested qPCR method and the microfluidic nested dPCR
for direct comparison of their performance. The nested
qPCR detection was conducted in 50 ml of reaction
volumes with a BCL2-specific cleavable probe sequence
(Figure 1c and d) to determine the threshold cycle (Ct)
values (Figure 1c and Supplementary Figure S2). The
dPCR methodology uses our custom-built MEGA
devices and a bead-based emulsion PCR assay (26) to
achieve high-throughput digital quantitation and single-
molecule sequencing of t(14;18) (Figure 1d). In this meth-
odology 2.5 nl of droplets serve as digital reaction volumes
and droplets containing both single copies of t(14;18) and
an IgH primer-functionalized bead yield clonal DNAbeads
labeled by fluorescein amidite (FAM)-labeled BCL2 primer
after thermal cycling. A portion of the post-PCR beads are
then analyzed by flow cytometry to quantify the target
copies. Remaining beads are used as templates for further
PCR amplification for single-molecule counting and
sequencing of the genetic variants of the mutation (Figure
1d).
Figure 2 directly compares the detection performance of
both nested assays using the standards of t(14;18)+gDNA
spiked into wild-type human gDNA. The qPCR method-
ology had an efficiency of 93.8% and a linear dynamic
range that spanned five log10 t(14;18) concentrations
(Figure 2a). Each 50 ml of reaction had a quantitative
limit of 3.3 106 copies of t(14;18) per genome (1
copy/mg gDNA) with an ultimate limit of detection of
106 copies of t(14;18) per genome (1 copy in 3 mg of
gDNA) (Figure 2a). The microfluidic nested dPCR tech-
nique offered quantitative detection down to a concentra-
tion of 106 copies t(14;18) per genome (1 copy in 3mg of
gDNA), and the theoretical detection limit was
determined to be 107 copies per genome as the experi-
mental signal is well above the background noise
(Figure 2b). Further dilutions of the lowest concentration
preamp standard were used to demonstrate quantitative
detection down to equivalent concentrations near
2 108 (Figure 2b, inset), indicating the detection and
quantitation limits of the microfluidic nested dPCR detec-
tion is constrained by the amount of DNA input
(maximum of 3 mg) that can be used in the 50 ml of
preamp reactions.
Digital detection and quantification of t(14;18) in
occupationally exposed subjects
To validate the microfluidic dPCR method for digital
analysis of rare t(14;18) mutations, we examined the clot
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Figure 1. Workflow and methodology for digital detection of t(14;18)
in the clot gDNA of healthy subjects. (A) The PCR strategy for t(14;18)
detection is illustrated by mapping the primers and probes used to their
genomic targets. The first round of PCR was primed with the outer
primer pair [consisting of an IgHJ consensus primer (JH Exo) and a
BCL2-specific primer (RT0001)]. The hemi-nested secondary rounds of
PCR were primed with a nested BCL2 primer (Nv3) while retaining the
use of the IgHJ consensus primer (JH Exo). (B) A preamp PCR (20
cycles) produced t(14;18) amplicon from 3 mg of clot gDNA. The
product of this first amplification step was then used as template in
secondary rounds of hemi-nested PCR. Two different types of quanti-
tative PCR were conducted: (C) standard qPCR using a BCL2-specific
Figure 1. Continued
fluorescent probe (see Supplementary Figure S2); and (D) microfluidic
emulsion single-molecule PCR using JH Exo-functionalized beads and
50-FAM-labeled Nv3 for t(14;18) detection. A microfluidic emulsion
generator array was used for high throughput (>106/h) production of
monodisperse reaction volumes. Following emulsion generation, the
nanoliter-scale reaction droplets were cycled to achieve single copy
genetic analysis of the template. If a copy of t(14;18) and a bead
were both present in a reaction droplet, then the bead was labeled
with fluorescent amplicon during PCR, otherwise beads remained un-
labeled. Beads were then recovered and analyzed by flow cytometry to
determine t(14;18) concentration within a sample. In addition, some of
the beads were distributed at 1 bead/well in 96-well plates to confirm
that FAM+ concentration among beads corresponds with t(14;18)+
concentration as determined using a BCL2-specific probe. This
tertiary round of amplification also produced sufficient template to
conduct standard sequencing reactions that were derived from single
molecule reactions.
Figure 2. Characterization of hemi-nested real-time PCR (qPCR) and
microfluidic dPCR assays for quantitation of the t(14;18) translocation.
(A) The hemi-nested qPCR analysis of t(14;18) copies spiked in
negative human genomic DNA shows a linear standard curve of the
threshold cycle (Ct) as a function of the t(14;18) concentration [copies
of t(14;18)/total genomic copies] with a dynamic range spanning five
orders of magnitude and a limit of detection near 106 copies t(14;18)/
genome. The error bars represent standard deviation (n=3). (B) The
hemi-nested microfluidic dPCR assay quantitatively measures t(14;18)
concentration with a limit of detection on the order of 107. The error
bars represent standard deviation (n 3). The inset demonstrates quan-
titative measurements of further dilutions (down to 1/50) of the pre-
amplified product from the lowest concentration standard [106
copies t(14;18)/genome]. The error bars indicate standard error.
e159 Nucleic Acids Research, 2013, Vol. 41, No. 16 PAGE 4 OF 11
gDNA samples of 93 healthy Chinese subjects, 42 of
whom had been occupationally exposed to formaldehyde.
All the samples were first characterized using the bulk
nested qPCR method (Figure 1b and c). Three aliquots
of 3 mg of gDNA from each subject were pre-amplified
and assayed (Figure 3a, circles under each subject
indicate number of assays). Two samples from Subjects
Q and X are included for internal quality control, giving
six reactions for each of these subjects. We found that
there were detectable levels of t(14;18) in 41 of 93
(44%) study subjects, as summarized in Figure 3a.
Thirty-two of these t(14;18)+ subjects show one or more
negative reactions (indicated by the open circles in
Figure 3a), presumably owing to the stochastic distribu-
tion of rare targets in the 3 mg of gDNA aliquots. The
overall concentration in these t(14;18)+ subjects ranged
Figure 3. Concentration of t(14;18) in positive study subjects. We detected t(14;18) in the clot gDNA of 41/93 healthy test subjects (44% preva-
lence). (A) Subject IDs are given on the abscissa, and the bar-height indicates the average concentration of t(14;18) in a given subject as determined
by the hemi-nested PCR techniques. The error bars indicate the standard deviation in the measurement. Below the subject ID on the abscissa, the
number of 3 mg of preamp reactions conducted on the subject’s gDNA is indicated by the total number of circles. Filled circles indicate that a preamp
reaction was positive by standard qPCR, whereas open circles indicate that the preamp reaction was found negative by standard qPCR. If an assay
circle is marked with the letter ‘e’, then that preamp reaction was also tested using microfluidic PCR, and in these cases, the quantitative result from
dPCR is also given. A box grouping preamp reactions indicates that these reactions were pooled before dPCR analysis. The data from these parallel
measurements (when positive) contributed data to part c of this figure. For all positive subjects, at least one clonal form of t(14;18) was confirmed by
sequence analysis; in some subjects, multiple clonal forms of t(14;18) were defined. If multiple clonal forms were found in a subject, the total number
of defined clones is indicated above the error bars. An asterisk indicates that one clonal form for that subject went undetected in qPCR and was then
discovered and/or defined in dPCR. (B) The dot scattered plot of the nested dPCR measurements of the preamp reactions showing the distinct
populations for the t(14;18) positive and negative subjects. The dashed line indicates the detection limit of 107 determined in Figure 2. (C) The two
methods represented in Figure 1c and d correlate well for quantitating t(14;18) both in cell line-derived DNA standards and in clot DNA samples
from chemically exposed workers. The horizontal error bars are standard error and the vertical error bars are standard deviation (n=2).
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from 7.7 105 (23 copies/mg) in Subject A down to
4 107 (a single copy in a total of 9 mg of gDNA
assayed) in Subject OO. The median level of t(14;18) in
the 41 positive study subjects was 2.23 copies/mg, and the
mean level of t(14;18) among the positive study subjects
was 3.83 copies/mg (genomic concentrations of 7.4 106
and 1.3 105, respectively). Furthermore, we used
sequencing and sequence analysis to definitively confirm
and fully define at least one clonal form in all 41 t(14;18)+
study subjects and to confirm that the forms of t(14;18)
found in these subjects were unique and different from
that found in the positive control CRL 2261 cell line. In
several subjects, more than one unique clonal form was
identified, and for these subjects, the total number of
t(14;18) clones identified is displayed above the bars for
each subjects (Figure 3a).
To assess the microfluidic-nested dPCR technology for
rare translocation detection and molecular profiling, we
focused our studies on the subjects with extremely low
concentration of t(14;18) and/or multiple clonal forms.
We analyzed a total of 69 preamp reactions, which con-
sisted of 50 positive reactions and 10 negative reactions
from 28 t(14;18)+ subjects (circles marked with ‘e’ in
Figure 3a) and 9 reactions randomly chosen from
t(14;18) subjects. The t(14;18) concentration results
obtained by the nested microfluidic dPCR analysis
agreed with those obtained by the standard qPCR. This
parallel comparison also demonstrated the robust nature
of both ultrasensitive assay variants. There was not a
single instance of disagreement between the two methods
for determination of positive/negative preamp reactions.
We assayed 10 negative preamp reactions from seven
positive subjects at the low end of t(14;18) concentration
as determined by qPCR. All the nested dPCR assays
yielded consistently negative results, a finding that
strongly suggests true negatives, given the sensitivity of
the methods used. Only one of the three preamp reactions
from many of the subjects contained t(14;18), and the
single positive qPCR trial for some subjects (e.g. subject
OO with a Ct value of 28.8), corresponded to 1 copy in
3 mg of gDNA, which suggests digital t(14;18) detection in
the single positive assay reaction for these subjects. These
observations demonstrate the ability of these nested
methodologies to detect a single copy of t(14;18) in 9 mg
of gDNA (relative genomic concentration of 4 107).
Thus, the overall clinical sensitivity of this method, like
other ultrasensitive techniques that achieve mutation de-
tection at the single copy level, is limited mainly by the
amount of gDNA available for screening (10,27).
The scatter plot of the nested dPCR measurements of
the preamp reactions (Figure 3b) shows that the positive
population is distinctly separated from the negatives,
which represent an extremely low background (below
genomic concentration of 107). Such detection perform-
ance and background level are consistent with those
obtained using the gDNA standards. The measured con-
centration of some positive reactions was lower than the
lowest concentration possible in our assays using 3 mg of
gDNA (1 106), which we found is largely attributed to
the degradation of DNA caused by the freeze-thaw of the
preamp samples. Regression of the parallel measurements
from the t(14;18)+ preamp reactions showed good correl-
ation between the microfluidic nested dPCR and the
standard nested qPCR (R2 0.75, Figure 3c). Overall,
these observations confirm that our nested dPCR method-
ology is ultrasensitive and capable of quantifying rare
mutations at concentrations of 106 and lower.
In addition, the same clonal form(s) of t(14;18) were
identified using both nested techniques for all positive
preamp reactions, except that an additional form of
t(14;18) was discovered by microfluidic nested dPCR for
two subjects (J and Q, note asterisks in Figure 3a). This
discovery demonstrates a key advantage of dPCR: single-
molecule analysis allows each clonal form to be amplified,
detected and quantified without competition from other
clonal forms, whereas a high concentration clonal form
can mask the presence of a less concentrated clone in
bulk analysis. Beyond the discovery of novel low-fre-
quency clones, the dPCR technique can also be used to
discretely amplify similarly sized clones that are contained
within a single sample, and thus allow these distinct clonal
forms to be resolved (see discussion of subjects H and HH
in the next ‘Results’ section). The results from single-mol-
ecule quantification and sequencing are detailed later in
the text.
Single-molecule sequencing to define and quantify
t(14;18) clones
To fully define the various t(14;18) clones and to
definitively confirm positive assay reactions, we purified
various clonal forms of t(14;18) by size using agarose gel
electrophoresis and then extracted the amplicons for
sequencing reactions. When multiple clones are present
in the same preamp reaction, the standard ‘bulk’ nested
qPCR technique yields multiple bands in the same lane,
and it is impossible to estimate the relative ratio of clonal
forms. However, when the same preamp reaction is
analyzed using the microfluidic nested dPCR technique,
each positive reaction droplet amplifies a single molecule
of t(14;18) amplicon (Figure 4 and Supplementary
Figure S3). The gel and sequencing data from single
molecule-derived sequencing reactions can then be used
to estimate the relative concentration of each clonal
form in a preamp reaction. Following the nested dPCR
from one particular preamp reaction conducted on subject
D, flow cytometry revealed that the resulting primer beads
were 27.8% positive for t(14;18) (Supplementary
Figure S3a). A representative section (19/96 wells) from
a plate of single-molecule sequencing reactions (1 bead/
reaction on average) is displayed in Figure 4 and reveals
close agreement in the concentration of beads that are
t(14;18)+ [6/19 (31.6%) versus 27.8%]. Further, this
section of the plate estimates the relative ratio of clone
1: clone 2 as 1:5 (Figure 4). More single-bead reactions
from two 96-well plates were considered and provided a
better quantitative agreement with cytometry [53/192
(27.6%) versus 838/3017 (27.8%)] and a more accurate
estimate of the ratio of clone 1: clone 2 as 18:37
(Supplementary Figure S3b). The overall Ct from qPCR
for this preamp reaction was 22.15, corresponding to 18
copies per mg or a genomic concentration of 6 105
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copies per genome. When the data from both methods are
considered, we can estimate that clone 1 is present at a
concentration of 2 105 copies per genome, and that
clone 2 is present at a concentration of 4 105 copies
per genome. This analysis demonstrates the key strength
of single molecule analysis via dPCR: each clonal form
can be uniquely quantified and tracked. We used this
approach to develop a quantitative map of the t(14;18)
landscape in our healthy Chinese study population (see
next ‘Results’ section).
Another advantage of dPCR is that the technique can
be used to resolve similarly sized clones carried by a
subject. Subjects H and HH carried similarly sized
clones, and the conventional bulk qPCR approach was
unable to resolve the clonal forms present in preamp re-
actions. In these cases, the various clones of t(14;18) that
were concurrent in preamp reactions were similar in size
and were not adequately separated on gel before purifica-
tion for sequencing reactions. Subsequent sequencing
reactions yielded reads with consensus near the Nv3
sequencing primer but with mixed traces as the clonal
forms diverged (Supplementary Figures S4a and S5a for
Subjects H and HH, respectively). Therefore, we used the
microfluidic nested dPCR method to discretely package
the various clonal forms of t(14;18) before nested ampli-
fication, and we then used a tertiary round of PCR to
produce sufficient amplicon for sequencing. In both
cases, dPCR and single-molecule-derived sequencing
allowed us to purify and define the similarly sized clones
of t(14;18) that were present in a particular preamp
reaction (Supplementary Figures S4b, c and S5b and c).
To assess the effect of sequencing errors, we used a
tracking sequence on the BCL2 side of the translocation,
which is less variable than the IgHJ side of the transloca-
tion. The tracking sequence (AGAGCCCTCCTGCCCT)
extends from position 3498 to position 3513 on
NM_000633.2, and it was chosen because it appears in
the vast majority of sequencing reads owing to both its
Figure 4. Definition and quantitation of clonal forms within subject samples. Representative results for the gel and sequence analysis of a single
subject (‘D’) who was found to be positive for two unique clonal forms of t(14;18). The gel bands were excised for sequencing reactions, and
sequence analysis defined the clonal forms of t(14;18) present in the sample. In bulk assays, both clonal forms amplify together, and it is not possible
to estimate their relative concentration. However, in digital microfluidic dPCR, the different clonal forms are discretely encapsulated in nanoliter-
scale reaction droplets along with primer-functionalized beads. The resulting digital reactions load individual beads with amplicon that represents
only a single form of the translocation. By simply counting the number of ‘large’ and ‘small’ bands or sequence reads, the relative ratio of clonal
forms within a sample can be estimated. In this gel section, the ratio of clone 1:clone 2 is 1:5, but gel analysis of more reactions from this subject
estimates the ratio as 18:37 (see Supplementary Figure S3b).
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proximity to the Nv3 sequencing primer and its distance
from most of the BCL2 breakpoints. The single exception
is that of clone 1 from Subject S; this clonal form [3507-N-
87331509 (BCL2-N-IgHJ)] had a BCL2 breakpoint at
3507 and therefore did not contain the complete
tracking sequence. Overall, we observed that 67% of all
sequencing reads from bead-based amplifications
contained no errors in this tracking sequence, whereas
33% of reads contained at least one error. The most
common type of sequencing error were insertions (50%
of all observed errors), whereas substitutions accounted
for 30% of all errors, and multiple errors accounted for
the remaining 20% of misread sequences. However, these
types of sequencing errors did not impact the results pre-
sented here, as each clonal form of t(14;18) was sequenced
multiple times, allowing a definitive consensus sequence to
be assembled, despite the presence of sequencing errors.
Quantitative genomic mapping of t(14;18) breakpoints
We defined all of the clonal forms present in positive assay
reactions and found that most positive subjects carried a
single unique t(14;18) clone, although nine subjects carried
two unique clonal forms and five subjects carried three
unique clonal forms. We used the dPCR method to
resolve each t(14;18) clone in subjects carrying multiple
clonal forms, and thus we were able to quantify the
relative amount of each clonal form. These relative
ratios were then scaled by the results from conventional
qPCR, which can only measure the total amounts of
t(14;18) within a subject, to quantify all 60 clonal forms
that were defined in this study. A quantitative genomic
map of the chromosome 14 and chromosome 18 break-
points for the 60 t(14;18) clones identified in this healthy
Chinese population shows typical breakpoint clustering
along both chromosomes for this translocation (Figure 5).
The chromosome 14 breakpoints were always found on
the heptamer side of V(D)J RSSs, with most chromosome
14 breakpoints occurring near the J4, J5 or J6 RSS
(Figure 5, Supplementary Figure S6, Supplementary
Table S1). This clustering on chromosome 14 is consistent
with the theory that errors in V(D)J recombination are
responsible for t(14;18) formation (23,28). We found
that t(14;18) breakpoints in the BCL-2 major breakpoint
region (MBR) on chromosome 18 cluster around positions
3520, 3571 and 3629 on NM_000633.2, consistent with
prior reports on FL cases and healthy individuals
(17,29). This quantitative genomic map of t(14;18) break-
points represents a baseline mutational landscape in these
study subjects, and a time-course of such measurements
could reveal clonal expansion on the path to lymphoma.
For complete details for all t(14;18) clones, including the
de novo ‘N sequence’ inserts, please see Supplementary
Table S1.
DISCUSSION
Droplet-based dPCR provides a powerful tool for sensi-
tive genetic analysis and has been reported for
Figure 5. Quantitative genetic profile of t(14;18) breakpoints in positive study subjects. The clonal form of t(14;18) defined in this study are
quantitatively mapped to their breakpoint coordinates on Chromosomes 14 (position on NT_026437.11) and Chromosomes 18 (position on
NM_000633.2). Most positive subjects (27/41) were positive for a single, unique form of t(14;18); however, 9/41 positive subjects were confirmed
to be positive for two unique clonal forms, and 5/41 were confirmed to be positive for three unique clonal forms (also see Figure 3 and
Supplementary Table S1). (A) The amount and coordinates of these 60 clonal forms of t(14;18) are mapped to a global genetic plot. The white
boxes on the plot indicate the locations of the IgHJ RSSs that direct V(D)J recombination. (B) A magnified view of each t(14;18) cluster is shown; all
clusters were found on the heptamer side of an IgHJ RSS. For details of sequence analysis results on these clonal forms, see Supplementary Table 1.
For details regarding the mapping of the IgHJ RSSs to NT_026437.11, see Supplementary Figure S6.
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quantitative detection of point mutations with detection
limits of 1 mutant allele in 104–105 wild-type copies
(8,9,30). Here, we demonstrated a nested microfluidic
dPCR that enables highly sensitive and quantitative detec-
tion of rare somatic translocation targets in a vast wild-
type DNA background. The hemi-nested primer design
reduces non-specific PCR amplification; however, we
found that significant improvement in sensitivity is
mainly conferred by using preamp reactions to increase
the amount of target sequence relative to the overall con-
centration of gDNA used in the dPCR assay and thus
decrease the interference from excessive background. We
tested gDNA NTCs [preamp of 3 mg of purely t(14,18)
gDNA] in dPCR and found that the percentage of false
FAM+beads was strongly dependent on the average con-
centration of gDNA in droplets. Excessive background
(>0.1% false FAM+ beads) was observed when
averaged concentrations were >0.1 genomic copies per
droplets (100 pg/ml), owing to non-specific amplification
of concentrated background gDNA in 2.5 nl of droplets.
Therefore, it is necessary to operate at 0.01–0.1 copies per
droplet to achieve highly sensitive detection. This oper-
ational limit results in a large dead volume during
droplet generation and lowers the effective throughput
of the dPCR assay when used to assay target mutations
directly. Preamp of the low concentration standards
allows us to use diluted gDNA concentration in dPCR,
which enable quantitative detection down to concentra-
tions of 1 107 or even lower (Figure 2b and inset)
while maintaining the analysis efficiency.
The microfluidic approach described here has digital
detection capability for highly quantitative measurement
of low-level t(14;18) mutations with single-molecule sensi-
tivity and resolution. Conventional qPCR assays de-
veloped here and by other researchers also conferred
single-molecule sensitivity to detect t(14;18) at 105 to
107 levels, depending on the amount of gDNA screened
(10,16,19,20,31–35). However, these analog measurements
remained semi-quantitative, especially at the low concen-
tration range (e.g. <105 in Figure 2a). Another distinct
advantage that the dPCR method offers over analog
qPCR assays is that it enables high-throughput targeted
single-molecule sequencing and allows various t(14;18)
clones to be resolved and quantified individually
(Figures 4 and 5). We demonstrated that the microfluidic
nested dPCR method provides single-molecule resolution
and enables identification, quantitation and genomic
mapping of unique t(14;18) clonal forms that are unresolv-
able using the conventional nested qPCR approach (see
data for subjects G, Q, H and HH in Figure 3a,
Supplementary Table S1 and Supplementary Figures S4
and S5). This technology thus could provide a powerful
tool for investigating the clonal evolution of cancer at the
single copy level. Clinical studies have identified clonal
evolution of t(14;18) in individual patients in response to
disease progression (23). A high-throughput technique
with the capability to sequence and quantify multiple
t(14;18)+ clones could provide insights into the molecular
pathology and clinical implication of t(14;18) (24,25). It
could also be used to detect rare cancer stem cells in a
large background of normal tissue. We may have
identified t(14;18)+ lymphoma stem cells in this study
population, but only continued monitoring in a large pro-
spective study can reveal whether particular t(14;18)+
clones expand and give rise to lymphoma. In addition,
in a previous report, we have demonstrated that this
bead-based dPCR technology can be adapted for multi-
plexed detection of multiple mutations in single cells,
which can provide even deeper insight into disease pro-
gression (36).
Furthermore, we demonstrated that our nested PCR
assays for t(14;18) can be used directly on gDNA from
whole blood or clot, a biological specimen that is easily
collected in population-based studies. With few excep-
tions, researchers assay for t(14;18) in hematopoietic cell
subpopulations that are enriched for B cells. We found
significant differences in the t(14;18) qPCR signal
provided by donor-matched PBMCs, buffy coat and
clot, with clot gDNA containing the lowest t(14;18) con-
centrations (Supplementary Figure S1). However, collec-
tion strategies in field-based studies of healthy populations
often cannot accommodate immediate blood fraction-
ation, and a high sensitivity and throughput t(14;18)
assay using clot gDNA of healthy individuals, such as
the method described here, would be useful in large pro-
spective cohort studies.
To our knowledge, this is the first time that a highly
sensitive t(14;18) assay has been applied to a healthy
Chinese population; though our group previously
applied a less sensitive assay to PBMC DNA in a
smaller Chinese population (37). This is also the first
study to apply microfluidic dPCR to monitor somatic
cancer mutations in occupationally exposed human
subjects. Through the use of the new microfluidic nested
dPCR technology, we detected, sequenced and quantified
60 t(14;18) clones found in 41 of 93 (44%) healthy
Chinese subjects. Our quantitative genomic mapping of
these t(14;18) clones revealed clustering within the MBR
region of BCL2 and within the IgHJ locus of chromosome
14, and the clustering we observed is consistent with
previous reports. Specifically, we observed clustering
within the MBR centered around positions 3520, 3571
and 3629 and mainly involving the J4, J5 and J6 RSSs
on the IgHJ locus—positions that are essentially identical
to those identified in prior reports in Western and North
American populations (17,29,38).
The t(14;18) translocation is thought to be an initiating
event in FL, and additional mutations after t(14;18) can be
associated with various outcome measures (17,24). A
study that used competitive genomic hybridization in
biopsies from t(14;18)+ FL cases showed that gain of
chromosome X in males and gains involving chromo-
somes 2, 3q and 5 were among copy number alterations
associated with poor outcome (39). Gene disruptions that
are frequently associated with adverse outcome in FL
cases include TNFRSF14 on 1p36 along with FAS and
TP53 on 10q and 17p, respectively (40). A cytogenetic
study of t(14;18)+ FL biopsies found that del(6q), +5,
+19 and +20 were associated with poorer overall
survival, and that del(17p) was associated with poorer
event-free survival (25). Although cytogenetics and FISH
offer information about mutation concurrence in single
PAGE 9 OF 11 Nucleic Acids Research, 2013, Vol. 41, No. 16 e159
cells, these methods are laborious, low-throughput and do
not provide sequence information. Most other modern
methods use homogenized samples, and there is no oppor-
tunity to achieve large-scale studies of mutation concur-
rence and synergy during disease progression at the single
cell level-where carcinogenesis ultimately occurs.
The dPCR and single-molecule sequencing technology
established here provides a promising platform for de-
veloping new approaches for high-throughput single-cells
analysis of the concurrence of multiple mutations.
Based on this digital microfluidic platform, we recently
developed a methodology for high-throughput purifica-
tion of single-cell genomes and multiple-allele sequencing
of single cells (36). Currently, the throughput of our
single-molecule/cell sequencing procedure is limited by
the use of second-round PCR to amplify the bead-bound
DNA for the standard Sanger sequencing. However, it is
feasible to adapt our bead-based dPCR method to
next-generation sequencing technologies for direct mas-
sively parallel sequencing off the post-PCR beads, thus
providing unprecedented throughput in single-cell
genetic analysis. We hope to soon extend this microfluidic
single cell analysis technology to an expanded set of
genetic markers of lymphoma and conduct multiple
allele sequencing of these regions at the single-cell level
in lymphoma biopsies. With these further developments,
we will add additional dimensions to the mutational land-
scape developed here so that we can begin to study FL
progression at the level of individual cancer stem cells.
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online,
including [26,41,42].
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